soul trial oral semaglutide cardiovascular outcomes results 2025 nejm in High-Risk Type 2 Diabetes: Benefit Confirmed in the SOUL (Semaglutide cardiOvascular oUtcomes triaL)
Description
510(k) exempt - for in vitro diagnostic use only.
New York pharmaceutical product liability attorney Leandros A
New research highlights that tailored, reduced doses of semaglutide with lifestyle coaching effectively prevent weight regain, demonstrating that lower doses are equally effective and sustainable
The available data suggest differences in the course of type 2 diabetes mellitus (T2DM) between men and women, influenced by the distinguishing features of the sex
